PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
121.05%
Some net income increase while AVXL is negative at -384.09%. John Neff would see a short-term edge over the struggling competitor.
473.10%
D&A growth of 473.10% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
20.60%
Deferred tax of 20.60% while AVXL is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-20.60%
Negative yoy SBC while AVXL is 0.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
534.15%
Well above AVXL's 165.36% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.02%
AP growth well above AVXL's 100.00%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
107.35%
Lower 'other working capital' growth vs. AVXL's 420.67%. David Dodd would see fewer unexpected short-term demands on cash.
-145.76%
Negative yoy while AVXL is 187.32%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-3.22%
Negative yoy CFO while AVXL is 20.11%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-7359.68%
Negative yoy CapEx while AVXL is 100.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth well above AVXL's 100.00%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
-7359.68%
We reduce yoy invests while AVXL stands at 100.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
37.62%
Debt repayment growth of 37.62% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
299.00%
Stock issuance far above AVXL's 11.60%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.